Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
19.3M
-
Number of holders
-
230
-
Total 13F shares, excl. options
-
17.3M
-
Shares change
-
+998K
-
Total reported value, excl. options
-
$1.45B
-
Value change
-
+$88M
-
Put/Call ratio
-
0.13
-
Number of buys
-
120
-
Number of sells
-
-96
-
Price
-
$84.26
Significant Holders of LIGAND PHARMACEUTICALS INC - Common Stock (LGND) as of Q2 2024
262 filings reported holding LGND - LIGAND PHARMACEUTICALS INC - Common Stock as of Q2 2024.
LIGAND PHARMACEUTICALS INC - Common Stock (LGND) has 230 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 17.3M shares
of 19.3M outstanding shares and own 89.47% of the company stock.
Largest 10 shareholders include BlackRock Inc. (2.87M shares), VANGUARD GROUP INC (1.93M shares), JANUS HENDERSON GROUP PLC (1.01M shares), MACQUARIE GROUP LTD (967K shares), DIMENSIONAL FUND ADVISORS LP (709K shares), STATE STREET CORP (689K shares), Stephens Investment Management Group LLC (652K shares), CONGRESS ASSET MANAGEMENT CO /MA (587K shares), Chicago Capital, LLC (515K shares), and VILLERE ST DENIS J & CO LLC (484K shares).
This table shows the top 230 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.